Prescient Therapeutics (PTX) has unveiled a novel adjuvant for enhancing cellular immunotherapy.
The CellPryme-A product was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTX’s CAR-T cell therapy. This is used to address the hostile tumour microenvironment that cellular immunotherapies face.
CellPryme-A can be administered either before or alongside cellular immunotherapy.
Prescient said in animal models, CellPryme-A had been shown to reduce the number of suppressive regulatory T cells surrounding solid tumours that counteracted the effectiveness of CAR-T and other cancer therapies.
While CellPrymeA demonstrated superior tumour killing and host survival in pre-clinical studies, its effects were even greater when used together with Prescient’s CAR-T manufacturing technology, CellPryme-M.
The company presented this new data at the seventh annual CAR-TCR Summit in Boston.
Prescient Managing Director and CEO Steven Yatomi-Clarke said the company was delighted to “finally” unveil CellPryme-A as a distinct but complementary addition to CellPryme-M.
“Together with Prescient’s next-generation CAR platform, OmniCAR, Prescient has placed itself enviably at the forefront of cellular immunotherapy by creating technologies that overcome the challenges facing the field,” Mr Yatomi-Clarke said.
The company said CellPryme-Awas now ready for clinical testing and could be incorporated into clinical studies of existing cell therapies.
Prescient Therapeutics was down 1.35 per cent and trading at 18 cents at 1:29 pm AEST.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。